Matsumoto Kotaro, Suzuki Katsuya, Yoshimoto Keiko, Ishigaki Sho, Yoshida Hiroto, Magi Mayu, Matsumoto Yoshihiro, Kaneko Yuko, Takeuchi Tsutomu
Division of Rheumatology Department of Internal Medicine Keio University School of Medicine Tokyo Japan.
Chugai Pharmaceutical Co. Ltd Kanagawa Japan.
Clin Transl Immunology. 2021 Jul 2;10(7):e1307. doi: 10.1002/cti2.1307. eCollection 2021.
Large vessel vasculitis (LVV) is characterised by a high relapse rate. Because accurate assessment of the LVV disease status can be difficult, an accurate prognostic marker for initial risk stratification is required. We conducted a comprehensive longitudinal investigation of next-generation RNA-sequencing data for patients with LVV to explore useful biomarkers associated with clinical characteristics.
Key molecular pathways relevant to LVV pathogenesis were identified by examining the whole blood RNA from patients with LVV and healthy controls (HCs). The data were examined by pathway analysis and weighted gene correlation network analysis (WGCNA) to identify functional gene sets that were differentially expressed between LVV patients and HCs, and associated with clinical features. We then compared the expression of the selected genes during week 0, week 6, remission and relapse.
The whole-transcriptome gene expression data for 108 samples obtained from LVV patients ( = 27) and HCs ( = 12) were compared. The pathway analysis and WGCNA revealed that molecular pathway related to interleukin (IL)-1 was significantly upregulated in LVV patients compared with HCs, which correlated with the positron emission tomography vascular activity score, a disease-extent score based on the distribution of affected arteries. Further analysis revealed that the expression levels of genes in the IL-1 signalling pathway remained high after conventional treatment and were associated with disease relapse.
Upregulation of the IL-1 signalling pathway was a characteristic of LVV patients and was associated with the extent of disease and a poor prognosis.
大血管血管炎(LVV)的特点是复发率高。由于准确评估LVV疾病状态可能具有挑战性,因此需要一种准确的预后标志物用于初始风险分层。我们对LVV患者的下一代RNA测序数据进行了全面的纵向研究,以探索与临床特征相关的有用生物标志物。
通过检测LVV患者和健康对照(HCs)的全血RNA,确定与LVV发病机制相关的关键分子途径。通过通路分析和加权基因共表达网络分析(WGCNA)对数据进行检查,以识别在LVV患者和HCs之间差异表达并与临床特征相关的功能基因集。然后我们比较了所选基因在第0周、第6周、缓解期和复发期的表达情况。
比较了从LVV患者(n = 27)和HCs(n = 12)获得的108个样本的全转录组基因表达数据。通路分析和WGCNA显示,与白细胞介素(IL)-1相关的分子通路在LVV患者中比HCs显著上调,这与正电子发射断层扫描血管活性评分相关,该评分是基于受影响动脉分布的疾病范围评分。进一步分析显示,IL-1信号通路中的基因表达水平在常规治疗后仍然很高,并且与疾病复发相关。
IL-1信号通路的上调是LVV患者的一个特征,并且与疾病程度和不良预后相关。